Novel therapeutic and diagnostic management of heart transplant patients
Open Access
- 1 January 2015
- journal article
- review article
- Vol. 7 (3) , 198-207
Abstract
Heart transplantation was performed for the first time 40 years ago and it is now universally considered the "gold standard" treatment for individuals suffering from end-stage heart failure. The increased understanding of the molecular mechanisms and of the role of the immune system in allograft rejection led to an overall improvement of graft survival, which is now around 10 years. The introduction of novel immunosuppressive drugs reduced the rate of acute allograft rejection but did not improve significantly the long-term graft survival. In addition, adverse effects (e.g. infections, cancer and renal failure) associated with immunosuppressive drugs are increasing over time and may affect post-transplantation outcomes. An immunosuppression-free protocol based on tolerance induction is the Holy Grail for heart transplant recipients, but it is still far beyond our reach. In this review, we discuss the landscape of immunological challenges that heart transplanted individuals face and we critically review the novel immunological approaches available to overcome these remaining issues. Some of the novel approaches, successfully tested in preclinical and clinical models, may lead to a prolongation of patient's and heart allograft survival.Keywords
This publication has 49 references indexed in Scilit:
- HLA-Mismatched Renal Transplantation without Maintenance ImmunosuppressionNew England Journal of Medicine, 2013
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report—2011The Journal of Heart and Lung Transplantation, 2011
- The Mobilization and Effect of Endogenous Bone Marrow Progenitor Cells in Diabetic Wound HealingCell Transplantation, 2010
- Proteomics Reveals Novel Oxidative and Glycolytic Mechanisms in Type 1 Diabetic Patients' Skin Which Are Normalized by Kidney-Pancreas TransplantationPLOS ONE, 2010
- Mammalian Target of Rapamycin Inhibition and Alloantigen-Specific Regulatory T Cells Synergize To Promote Long-Term Graft Survival in Immunocompetent RecipientsThe Journal of Immunology, 2009
- MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in MiceScience, 2009
- The inhibitory cytokine IL-35 contributes to regulatory T-cell functionNature, 2007
- Importance of Donor- and Recipient-Derived Selectins in Cardiac Allograft RejectionJournal of the American Society of Nephrology, 2007
- Cross-Sectional Assessment of the Effect of Kidney and Kidney-Pancreas Transplantation on Resting Left Ventricular Energy Metabolism in Type 1 Diabetic-Uremic PatientsJACC, 2005
- Simvastatin Initiated Early After Heart TransplantationCirculation, 2003